BackgroundStudies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer.MethodsMEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment. Secondary outcomes included overall and R0 resection rate, pathological lymph node rate, reasons for unresectability and toxicity of neoadjuv...
Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resecti...
PURPOSE: The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancre...
Pancreatic adenocarcinoma is a devastating disease with only 15–20% of patients resectable at diagno...
Background: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may re...
Introduction: Neoadjuvant therapy may improve survival compared with upfront surgery in patients wit...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
BACKGROUND: Neoadjuvant treatment frequently is performed in unresectable/borderline resectable p...
Xiaohan Ren,1 Xiyi Wei,1,* Yichao Ding,1,* Feng Qi,2,* Yundi Zhang,1 Xin Hu,1 Chao Qin,2 Xiao Li3 1D...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
[[abstract]]BACKGROUND: Upfront resection (UR) followed by adjuvant chemotherapy remains the standar...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
BACKGROUND: The role of neoadjuvant therapy remains controversial for resectable pancreatic neoplasm...
<p><b>Background:</b> Neoadjuvant therapy for pancreatic cancer remains controversial. Our aim was t...
Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resecti...
PURPOSE: The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancre...
Pancreatic adenocarcinoma is a devastating disease with only 15–20% of patients resectable at diagno...
Background: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may re...
Introduction: Neoadjuvant therapy may improve survival compared with upfront surgery in patients wit...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
BACKGROUND: Neoadjuvant treatment frequently is performed in unresectable/borderline resectable p...
Xiaohan Ren,1 Xiyi Wei,1,* Yichao Ding,1,* Feng Qi,2,* Yundi Zhang,1 Xin Hu,1 Chao Qin,2 Xiao Li3 1D...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
[[abstract]]BACKGROUND: Upfront resection (UR) followed by adjuvant chemotherapy remains the standar...
ObjectiveTo investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to up...
BACKGROUND: The role of neoadjuvant therapy remains controversial for resectable pancreatic neoplasm...
<p><b>Background:</b> Neoadjuvant therapy for pancreatic cancer remains controversial. Our aim was t...
Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resecti...
PURPOSE: The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancre...
Pancreatic adenocarcinoma is a devastating disease with only 15–20% of patients resectable at diagno...